Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series
Immune checkpoint inhibitors (ICIs) targeting cytotoxic Tlymphocyte associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and its ligand PD-L1 are established cancer immunotherapies for solid tumor and hematologic malignancies. These therapies are involved in immune-related adverse...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Verduci Editore
2021-08-01
|
| Series: | Beyond Rheumatology |
| Subjects: | |
| Online Access: | https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/05/br-3-2-65.pdf |